Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$42.91 ▲ +1.82
(+4.43%)
MKT CAP: $2.20B • VOL: 544.9K
52W L $29 52W H $49
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$36
MEDIAN
$48
MEAN
$49
HIGH
$58
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VCEL TAPE
VCEL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $51.92 | $49.35 | 2025-02-14 | $39.05 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $54.07 | $50.63 | 2025-02-06 | $40.34 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $48.92 | $47.20 | 2025-01-29 | $41.19 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $43.77 | — | 2025-01-17 | $42.05 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $37.76 | $40.76 | 2025-01-09 | $38.19 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $51.06 | $44.63 | 2024-12-18 | $37.33 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $41.62 | $43.34 | 2024-12-04 | $39.91 | -4.3% | 48% | C |